Attitudes des médecins généralistes et endocrinologues face à la dysfonction érectile du patient diabétique : enquête auprès de 130 patients

Autor: Tardieu, A., Khodari, M., Palazzi, J., Ajzenberg, C., Yiou, R.

Publikováno v: In Progres en Urologie 2011 21(2):126-133

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Intellectual disability in patients with MODY due to hepatocyte nuclear factor 1B (HNF1B) molecular defects

Autor: Dubois-Laforgue, C, Bellanné-Chantelot, B, Charles, C., Jacquette, J, Larger, C, Ciangura, C., Saint-Martin, C., Rastel, C., Keren, B., Timsit, J., Dubois-Laforgue, D., Ajzenberg, C., Azar, R., Badet, E., Baechler-Sadoul, E., Barrande, G., Bertin, E., Bony, H., Gross, M., Bouché, C., Gautier, J.F., Guillausseau, P., Bourcigaux, N., Jacquesson, L., Bruzeau, J., Lefort, G., Colmar-Montiel, C., Cordonnier, M., Couzi, L., Delgrange, E., Pasquier, D., Ronco, P., Dupont, J., Dusselier, L., El Etr, M., Franchini, A., Godart, C., Vincent-Dejean, C., Guemazi, F., Jeanjean, E., Jeanne, S., Loric, S., Joubert, M., Reznik, Y., Kaloustian, E., Kessler, L., Pâris-Bockel, D., Perrin, P., Kitzis, A., Lemoine, A., Le Penher, D., Perlemoine, C., Lesire, V., Smati, D., Le Thai, F., Lévy, D., Maury, E., Moulin, P., Pierre, P., Plat, F., Poynard, J.P., Raffin-Sanson, M.L., Coz, S., Requeda, E., Roussey-Kesler, G., Schillo, F., Subra, J.F., Sonnet, E., Valéro, R., Vantyghem, M.C., Wautelet, R., Wojtusciszyn, A.

Publikováno v: Journal of Diabetes & Metabolism
Journal of Diabetes & Metabolism, OMICS International, 2017, 43 (1), pp.89-92. ⟨10.1016/j.diabet.2016.10.003⟩
Journal of Diabetes & Metabolism, 2017, 43 (1), pp.89-92. ⟨10.1016/j.diabet.2016.10.003⟩
Endocrinology, Diabetes & Metabolism
Endocrinology, Diabetes & Metabolism, Wiley, 2017, 43 (1), pp.89-92. ⟨10.1016/j.diabet.2016.10.003⟩

Diabetes & Metabolism - In Press.Proof corrected by the author Available online since jeudi 10 novembre 2016

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bb42ab189e54c6c1efbe188e54caef2
https://hal.umontpellier.fr/hal-01801737

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

Autor: Caron, Philippe J, Bevan, John S., Petersenn, Stephan, Houchard, Aude, Sert, Caroline, Webb, Susan M., Van Gaal, L, Marek, J, Nuutila, P, Välimäki, M, Ajzenberg, C, Borson Chazot, F, Brue, T, Caron, P, Chabre, O, Chanson, P, Rudelli, C, Delemer, B, Kuhn, J, Tabarin, A, Badenhoop, K, Berg, C, Petersenn, S, Schöfl, C, Schopohl, J, Cannavo', Salvatore, Colao, A, De Marinis, L, Stades, A, van der Lely, Aj, Kadıoğlu, Tp, Bevan, Js, Flanagan, D, Trainer, P.

Publikováno v: Pituitary
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Purpose To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data. Methods PRIMARYS was a 1-year, open-label study of lanreotide Autogel (Depot in USA) 120 mg every 4 week

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8497d8b8e366086274f26407e98db84
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7395

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly : results of a prospective multicenter clinical trial

Autor: Caron, Pj, Bevan, Js, Petersenn, S, Flanagan, D, Tabarin, A, Prévost, G, Maisonobe, P, Clermont, A, Van Gaal Luc, L, Marek, J, Nuutila, P, Välimäki, M, Ajzenberg, C, Borson Chazot, F, Brue, T, Caron, P, Chabre, O, Chanson, P, Rudelli, C, Delemer, B, Kuhn, Jm, Badenhoop, K, Berg, C, Schöfl, C, Schopohl, J, Cannavo', Salvatore, Colao, A, De Marinis, L, Stades, A, Van der Lely, A, Kadioğlu, P, Bevan, J, Trainer, P.

Publikováno v: The Journal of Clinical Endocrinology and Metabolism

Context: Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly. There are also limited data for the long-acting lanreotide formulation. Objective: The aim of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe4c9adf02c6458fc2730abcdd42cd2
https://www.ncbi.nlm.nih.gov/pubmed/24423301